<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03059992</url>
  </required_header>
  <id_info>
    <org_study_id>SCY-078-301</org_study_id>
    <secondary_id>2017-000381-29</secondary_id>
    <nct_id>NCT03059992</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment</brief_title>
  <acronym>FURI</acronym>
  <official_title>Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 (Ibrexafungerp) in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scynexis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Scynexis, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open label, non-comparator, single arm study to evaluate the efficacy
      and safety of ibrexafungerp (SCY-078) in patients ≥ 18 years of age with a documented fungal
      disease that has been intolerant or refractory (rIFI) to Standard of Care (SoC) antifungal
      treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open label, non-comparator, single arm study to evaluate the efficacy
      and safety of ibrexafungerp in patients ≥ 18 years of age with a documented invasive and/or
      severe fungal disease that has been intolerant or refractory (rIFI) to Standard of Care (SoC)
      antifungal treatment. Patients will be treated with ibrexafungerp for up to 180 days.
      Treatment beyond 180 days and combination therapy with other antifungal agents may be allowed
      under special circumstances to be agreed upon by the Investigator and the Sponsor.

      Subjects must have a proven or probable fungal disease and meet all study criteria to be
      considered for enrollment. Eligible subjects must also have documented evidence of failure
      of, intolerance to, or toxicity related to a currently approved SoC antifungal treatment.

      Subjects will also be considered for enrollment if they have an eligible fungal disease and,
      in the judgement of the investigator, the subject cannot receive approved oral antifungal
      options (e.g. susceptibility of the organism or risk for drug-drug interactions) and a
      continued IV antifungal therapy is not desirable or feasible due to clinical or logistical
      circumstances.

      Following a screening visit, there will be up to 15 treatment visits, a follow-up visit and 2
      follow-up contacts.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label, non-comparator, single arm</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of Global Response</measure>
    <time_frame>Up to 180 days of study treatment</time_frame>
    <description>The proportion of subjects with a complete or partial Global Response (GR) at the End of Treatment Visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of Recurrence of Baseline Fungal Infection</measure>
    <time_frame>up to 42 days after end of study treatment</time_frame>
    <description>The proportion of subjects with a recurrence of the baseline fungal infectoin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of survival</measure>
    <time_frame>Day 42, Day 84</time_frame>
    <description>Proportion of surviving subjects</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Invasive Candidiasis</condition>
  <condition>Mucocutaneous Candidiasis</condition>
  <condition>Coccidioidomycosis</condition>
  <condition>Histoplasmosis</condition>
  <condition>Blastomycosis</condition>
  <condition>Chronic Pulmonary Aspergillosis</condition>
  <condition>Allergic Bronchopulmonary Aspergillosis</condition>
  <condition>Invasive Pulmonary Aspergillosis</condition>
  <condition>Recurrent Vulvovaginal Candidiasis</condition>
  <condition>Other Emerging Fungi</condition>
  <arm_group>
    <arm_group_label>Ibrexafungerp (SCY-078)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibrexafungerp (SCY-078), orally administered QD for up to 180 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrexafungerp</intervention_name>
    <description>Experimental Study Drug</description>
    <arm_group_label>Ibrexafungerp (SCY-078)</arm_group_label>
    <other_name>SCY-078</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Must have a documented eligible invasive and/or severe fungal disease that is
             refractory or intolerant to Standard-of-Care treatment

          2. Be able to tolerate medication orally or through a nasogastric (NG) tube or
             percutaneous endoscopic gastrostomy (PEG) tube

          3. Be able to understand and sign a written informed consent form (ICF), which must be
             obtained prior to treatment and any study-related procedures.

          4. Be able to understand and sign a consent or authorization form which shall permit the
             use, disclosure and transfer of the subject's personal health information. (e.g., in
             the U.S. HIPAA Authorization form).

          5. Be able to understand and follow all study-related procedures including study drug
             administration.

          6. Agree to use a medically acceptable method of contraception while receiving
             protocol-assigned product.

        Key Exclusion Criteria:

          1. An invasive fungal disease with CNS involvement.

          2. Subject has an inappropriately controlled fungal disease source (e.g., persistent
             catheters that cannot be removed and are likely the source of infection).

          3. Subject is hemodynamically unstable, requiring vasopressor medication for blood
             pressure support.

          4. A life expectancy &lt; 30 days.

          5. Subject with abnormal liver test parameters: aspartate aminotransferase (AST), alanine
             aminotransferase (ALT) &gt;10 x the upper limit of normal (ULN), and/or total bilirubin &gt;
             5 x ULN.

          6. Subject is pregnant or lactating.

          7. Subject has used an investigational drug within 30 days prior to the baseline visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Angulo, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sponsor GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nkechi Azie, MD</last_name>
    <phone>201-688-2243</phone>
    <email>nkechi.azie@scynexis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristin Bennett</last_name>
    <phone>201-884-5469</phone>
    <email>kristin.bennett@scynexis.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-0006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alisa Pinhehardt</last_name>
      <phone>205-934-9661</phone>
      <email>apeinhardt@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Pappas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kate Trigg</last_name>
      <phone>916-734-8033</phone>
      <email>ktconant@ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>George Thomposn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital Midtown</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia Carpentieri</last_name>
      <phone>404-712-7245</phone>
      <email>cynthia.t.smith@emory.edu</email>
    </contact>
    <investigator>
      <last_name>George Lyon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aprile Osborn</last_name>
      <phone>706-721-0309</phone>
      <email>aosborn@augusta.edu</email>
    </contact>
    <investigator>
      <last_name>Jose Vazquez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Randee Estees</last_name>
      <phone>773-702-1209</phone>
      <email>restes@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Kathleen Mullane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Louisiana State University Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Weiser</last_name>
      <phone>504-210-3403</phone>
      <email>sweise@lsuhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Hagensee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Louisiana State University</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Weiser</last_name>
      <phone>504-568-7740</phone>
    </contact>
    <investigator>
      <last_name>Michael Hagensee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Casey Dahl</last_name>
      <phone>612-626-3798</phone>
      <email>dahl0465@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Jo-Anne Young, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Kessels</last_name>
      <phone>314-747-1096</phone>
    </contact>
    <contact_backup>
      <email>lkessels@wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Andrej Spec, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Walsh, MD</last_name>
      <phone>212-746-6320</phone>
      <email>thw2003@med.cornell.edu</email>
    </contact>
    <contact_backup>
      <last_name>Roxanne Rosario</last_name>
      <phone>1-646-962-3090</phone>
      <email>ror2030@med.cornell.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas Walsh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Medical Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastian Munoz</last_name>
      <phone>631-638-0844</phone>
      <email>sebastian.munoz@stonybrookmedicine.edu</email>
    </contact>
    <investigator>
      <last_name>Roderick Go, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Wright</last_name>
      <phone>919-668-5571</phone>
      <email>diane.wright@dm.duke.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Libyadda Mosley</last_name>
      <phone>336-716-3266</phone>
      <email>limosley@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>John Sanders, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburg Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa Lingg</last_name>
      <phone>412-648-6536</phone>
      <email>linggtm@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Minh-Hong Nguyen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37325</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheri Dixon</last_name>
      <phone>615-343-0266</phone>
      <email>sheri.dixon@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Gowri Satyanarayana, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8589</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giselle Huet</last_name>
      <phone>214-648-9464</phone>
      <email>giselle.huet@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Ricardo LaHoz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelbie Martin</last_name>
      <phone>713-704-4137</phone>
      <email>shelbie.a.martin@uth.tmc.edu</email>
    </contact>
    <investigator>
      <last_name>Luis Ostrosky-Zeichner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Arnold, MD</last_name>
      <phone>434-996-7623</phone>
      <email>cja4j@hscmail.mcc.virginia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mary Marshall</last_name>
      <phone>1-434-924-2804</phone>
      <email>mhm2m@virginia.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meg Bayless</last_name>
      <phone>608-262-8156</phone>
    </contact>
    <investigator>
      <last_name>David Andes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of Graz Department of Internal Medicine, Department of Pulmology, Section for Infectious Disease and Tropical Medicine</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jurgen Prattes</last_name>
      <phone>+43 316 385 30046</phone>
    </contact>
    <investigator>
      <last_name>Robert Krause, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petra Decristoforo</last_name>
      <phone>0049 6676 8716 72722</phone>
      <email>petra.decristoforo@i-med.ac.at</email>
    </contact>
    <investigator>
      <last_name>Günter Weiss, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephan Eschertzhuber, Prof. Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Köln, Klinik I für Innere Medizin</name>
      <address>
        <city>Cologne</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanna Proske</last_name>
      <phone>0221 478-85504</phone>
      <email>susanna.proske@uk-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Oliver Cornely, Prof MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen, Klinik für Infektiologie</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerlinde Augustiniak</last_name>
      <phone>0049 201 723 6022</phone>
      <email>gerlinde.augustiniak@uk-essen.de</email>
    </contact>
    <investigator>
      <last_name>Oliver Witzke, Prof MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt, Department of Internal Medicine II</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franziska Ebeling</last_name>
      <phone>0049 69 6301 6140</phone>
      <email>franziska.ebeling@kgu.de</email>
    </contact>
    <investigator>
      <last_name>Christoph Stephan, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum St. Georg gGmbH Department for Infectious Disease, Tropical Medicine and Nephrology</name>
      <address>
        <city>Leipzig</city>
        <zip>04129</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrike Schmidt</last_name>
      <phone>0049 341 909 4472</phone>
      <email>ulrike.schmidt@sanktgeorg.de</email>
    </contact>
    <investigator>
      <last_name>Bernhard Ruf, Prof MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LMU Klinikum der Universität München, Medizinische Klinik und Poliklinik III</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Illenyi</last_name>
      <phone>0049 89 4400 75211</phone>
      <email>marta.illenyi@med.uni-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Helmut Ostermann, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Center, Department of Medicine Geert Grooteplein Zuid 8</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6525</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof. Bart-Jan Kullberg, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Munoz, MD</last_name>
      <phone>0034 914 265 184</phone>
      <email>pmunoz@hggm.es</email>
    </contact>
    <investigator>
      <last_name>Patricia Munoz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Tasias, MD</last_name>
      <phone>0034 96 124 40 00</phone>
      <email>marionatasias@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Josefa Monzón Soriano</last_name>
      <phone>0034 96 124 40 00</phone>
      <phone_ext>440517</phone_ext>
    </contact_backup>
    <investigator>
      <last_name>Maria Tasias, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Manchester</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9PL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Riina Richardson, MD</last_name>
      <phone>0044 75 459 949 59</phone>
      <email>Riina.Richardson@manchester.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Karen Rhodes</last_name>
      <phone>0044 (0)161 291 5768</phone>
      <email>karen.rhodes@mft.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Riina Richardson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Davis MR, Donnelley MA, Thompson GR. Ibrexafungerp: A novel oral glucan synthase inhibitor. Med Mycol. 2020 Jul 1;58(5):579-592. doi: 10.1093/mmy/myz083.</citation>
    <PMID>31342066</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>February 14, 2017</study_first_submitted>
  <study_first_submitted_qc>February 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2017</study_first_posted>
  <last_update_submitted>October 23, 2019</last_update_submitted>
  <last_update_submitted_qc>October 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Aspergillosis</mesh_term>
    <mesh_term>Candidiasis, Invasive</mesh_term>
    <mesh_term>Candidiasis, Vulvovaginal</mesh_term>
    <mesh_term>Pulmonary Aspergillosis</mesh_term>
    <mesh_term>Histoplasmosis</mesh_term>
    <mesh_term>Invasive Pulmonary Aspergillosis</mesh_term>
    <mesh_term>Aspergillosis, Allergic Bronchopulmonary</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Coccidioidomycosis</mesh_term>
    <mesh_term>Blastomycosis</mesh_term>
    <mesh_term>Candidiasis, Chronic Mucocutaneous</mesh_term>
    <mesh_term>Coccidiosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

